

Neonatal Infection Guideline Update- Committee Meeting

Date: 9th and 10th September 2020

Location: Virtual committee meeting by Zoom

Minutes: Final

| Committee members present: | Session one | Session two |
|-----------------------------------|--|--|
| Waqaar Shah (WS) (Chair) | Present for items 1 - 5 | Present for items 1 - 5 |
| Sumiah Al-Azeib (SA) | Present for items 1 - 5 | Present for items 1 - 5 |
| Jim Gray (JG) | Present for items 1 - 5 | Present for items 1 - 5 |
| Mark Davies (MD) | Present for items 1 - 5 | Present for items 1 - 5 |
| Jane Plumb (JP) | Present for items 1 - 5 | Present for items 1 - 5 |
| Richard Tubman (RT) | Present for items 1 – 5 (in and out due to clinical commitments) | Present for items 1 – 5 (in and out due to clinical commitments) |
| Aung Soe (AS) | Present for items 1 - 5 | Present for items 2 - 5 |
| Philip Banfield (PB) | Present for items 1 - 5 | Present for items 1 - 5 |
| Stephanie Jenkins (SJ) | Present for items 1 - 5 | Apologies |
| Paul Heath (PH) | Present for items 1 – 5 (left between 2.30 – 3pm) | Present for items 1 – 5 |

| | | |
|---|-------------------------|-------------------------|
| Clare Dadswell (CD) Technical Analyst | Present for items 1 - 5 | Present for items 1 - 5 |
| Kathryn Hopkins (KH) Technical Adviser | Present for items 1 - 5 | Present for items 1 - 5 |
| Catrina Charlton (CC) Guideline Commissioning Manager | Apologies | Present for items 1 - 5 |
| Gabriel Rogers (GR) Technical Adviser Health Economics | Present for items 1 - 5 | Present for items 1 - 5 |
| Jeremy Dietz (JD) Technical Analyst Health Economics | Present for items 1 - 5 | Present for items 1 - 5 |
| Susan Spiers (SS) Associate Director – Guideline Updates Team | Apologies | Present for items 1 - 3 |

| | | |
|--|-------------------------|-------------------------|
| Adam Storrow (AS) Business Analyst – Resource Impact | Present for items 1 - 5 | Present for items 1 – 5 |
| Anneka Patel (AP) Project Manager | Present for items 1 - 5 | Present for items 1 - 5 |
| Gareth Haman (GH) Senior Medical Editor | Present for items 1 - 5 | Present for items 1 - 5 |

| Apologies: | |
|-------------------|----------------|
| Melanie Carpenter | Midwife |
| Nicole Gannon | Health Visitor |

| NICE observers in attendance | |
|-------------------------------------|--------------------------------------|
| Lucy Beggs (session one only) | Technical Adviser (Health Economics) |

Session one – 9th September 1 – 3.30pm

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to session one of the 10th meeting on Neonatal infections.

The Chair informed the Committee that apologies from Melanie Carpenter and Nicole Gannon had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- The clinical and cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was: prevention and treatment of neonatal infection.

The DOI register was reviewed by the Chair and Committee and the Chair asked everyone to verbally declare any interests that have arisen since the last meeting. These are noted below.

| Name | Job title, organisation | Declarations of Interest, date declared | Type of interest | Decision taken |
|----------|-------------------------|--|-------------------|-------------------------|
| Aung Soe | Neonatologist | Received payment from AbbVie for lecturing on Bronchopulmonary Dysplasia and Respiratory Syncytial Virus | Direct, financial | Declare and participate |

| | | | | |
|--|--|-------------------|--|--|
| | | infection Webinar | | |
| <p>The DOIs were considered by the Chair, no conflict of interest was identified for the meeting, and all Committee members were eligible to attend the Committee meeting and contribute to the discussions.</p> <p>The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed the minutes were a true and accurate account of the meeting which took place on the 26th August 2020.</p> | | | | |
| <p>2. RQ 7.2 What is the clinical and cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection?</p> <ul style="list-style-type: none"> • Presentation of clinical evidence | | | | |
| <p>The Chair introduced CD, Technical Analyst, who gave a presentation on starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection. The Chair thanked CD for their presentation.</p> | | | | |
| <p>3. RQ 7.2 What is the clinical and cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection?</p> <ul style="list-style-type: none"> • Presentation of health economic model | | | | |
| <p>The Chair introduced JD, Technical analyst for Health economics, who gave a presentation of the health economic model for this area. The Chair thanked JD for their presentation.</p> | | | | |
| <p>4. RQ 7.2 What is the clinical and cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection?</p> <ul style="list-style-type: none"> • Draft recommendations | | | | |
| <p>The Chair led a Committee discussion on the evidence and health economic modelling presented. The Committee drafted one new recommendation in this area. The Chair thanked the Committee for their contributions and advised this could be revisited briefly in session two.</p> | | | | |
| <p>5. AOB, summary and next steps</p> | | | | |
| <p>There was no other business noted, and next steps would be covered at the end of session two.</p> <p>The Chair thanked the Committee for their time and contribution to the meeting</p> | | | | |

Session two – 10th September 1 – 3.30pm

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to session two of the 10th

meeting on Neonatal infections.

The DOI register was reviewed by the Chair and Committee and the Chair asked everyone to verbally declare any interests that have arisen since the last meeting. No further DOIs were noted.

2. Neonatal infection: antibiotics for prevention and treatment

- **Equalities considerations and discussion**

The Chair introduced KH, Technical Adviser, who went through the equalities considerations for this guideline update. The Chair thanked KH for their presentation.

3. Neonatal infection: antibiotics for prevention and treatment

- **Revisiting of draft recommendations (short guideline)**

The Chair introduced KH, Technical Adviser, who went through the updated short guideline with all draft recommendations made by the committee. The Chair thanked KH for their presentation.

4. Neonatal infection: antibiotics for prevention and treatment

- **Revisiting of research recommendations**

The NICE team will create an online survey to complete this and ask Committee members to choose up to 5 of the 8 research recommendations to take forward.

5. AOB, summary and next steps

The Chair thanked the Committee for their time and contribution to the meeting and throughout the development of this guideline update.

AP, Project Manager, advised of next steps and key dates for the guideline going out to public consultation.

The next meeting (post consultation) was confirmed as below.

Date of next meeting: 26th January 2021 9.30am – 5pm

Location of next meeting: Virtual committee meeting by Zoom